[Hiring] Health Economics & Outcomes Research Intern @Iovance Biotherapeutics

Role Description

The HEOR summer intern will actively contribute to various HEOR projects supporting health economic modelling, HTA submissions, real-world evidence generation, literature searches and evidence synthesis. The intern will work with cross-functional teams and interact with key internal stakeholders as well as external vendors to improve the clinical value demonstrations and value propositions for lifileucel.

Responsibilities

• Support for HEOR projects – health economic modelling (e.g. indirect treatment comparisons), assist with literature reviews and evidence synthesis; cost effectiveness and budget impact analyses.
• Interpretation and communication of quantitative and qualitative findings to internal and external audiences.
• Investigation of optimal HEOR methodologies for long-term economic evaluation of lifileucel.

Qualifications

• Currently pursuing Masters or PhD degrees in Health Economics, Outcomes Research, Pharmacoeconomics, Epidemiology, Health Services Research or related discipline.
• Strong academic record (with a GPA > 3.2) with a record of core HEOR foundational course work and/or research methodology training.
• Ability to communicate professionally and succinctly via email, Teams, and Zoom.
• Excellent written and oral communication skills.
• Experience and competency in using MSOffice skills (Outlook, Word, Excel, PowerPoint).
• Statistical analysis skills in R, STATA, SAS or Microsoft Visual Studio C++.

Requirements

• Enrollment in a graduate degree program at a US institution. Candidate shall not be graduating sooner than September 2026.
• Candidates must reside in USA. Execution of tasks and responsibilities will be on a remote basis through candidate’s virtual office space.

Expected Start and Duration

• The summer internship program will commence in May and last 12 weeks.

Pay Transparency

• $21 — $22 USD

Company Description

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer.